Test Price
2,800 AED✅ Home Collection Available
GNAS Gene Pseudopseudohypoparathyroidism Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed Consultant Medical Genetics.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This single-gene NGS test comprehensively analyzes the GNAS gene for pseudopseudohypoparathyroidism—a rare endocrine disorder within the Albright hereditary osteodystrophy spectrum—ensuring precise differentiation from pseudohypoparathyroidism.
| Feature | Our ISO NGS Test | Closest Alternative (Sanger) |
|---|---|---|
| Method | NGS (Next Generation Sequencing) | Sanger Sequencing (limited regions) |
| Diagnostic Precision | 99.9% coverage of all GNAS exons & splice sites | High for targeted mutations, may miss deep intronic variants |
| Turnaround Time | 3 – 4 Weeks | 2 – 3 Weeks |
| Accreditation | ISO 9001:2015 + DHA Licensed | Variable; often lacks ISO certification |
| UAE Legal Compliance | Full PDPL & Federal Law No. 2 of 2019 adherence | May not meet local genomic data regulations |
Physician Insight & Safety Protocols
“Every GNAS variant must be interpreted in the clinical context of Albright hereditary osteodystrophy. As a Consultant Medical Genetics, I advise that this test is a powerful tool when combined with a thorough phenotypic assessment; a negative result does not exclude related disorders. Please continue all prescribed medications and attend your specialist follow‑up to correlate the genetic findings with your health status.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Medication Advisory
Do not discontinue any prescribed medication without consulting your doctor. This genetic test is elective and does not require changes to your current regimen.
Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria:
- Patients unable to provide informed consent or lacking a legally authorised representative.
- Minors (<18) without court‑appointed guardian consent, as mandated by Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Specimens that do not meet cold‑chain requirements or are haemolysed.
ER Red Flags — Seek immediate medical attention if:
- You are currently experiencing severe hypocalcaemia symptoms (tetany, seizures, cardiac arrhythmia) – this genetic test is elective and not for acute diagnosis.
- You develop sudden mental status changes, atypical fractures, or signs of severe mineral imbalance.
- A genetic report indicating a pathogenic GNAS variant is accompanied by alarming physical symptoms – contact your doctor immediately.
Patient FAQ & Clinical Guidance
1. What is the GNAS gene pseudopseudohypoparathyroidism test?
The NGS test screens full GNAS gene mutations causing Albright hereditary osteodystrophy variants, including pseudopseudohypoparathyroidism, using a single blood or DNA sample for comprehensive diagnosis.
This advanced genetic test reads the entire coding region of the GNAS gene to detect even rare pathogenic variants that explain your clinical features. It differentiates pseudopseudohypoparathyroidism (normal calcium) from pseudohypoparathyroidism, guiding appropriate endocrine and genetic management.
2. How accurate is this DNA test?
The ISO-certified NGS panel achieves >99.9% diagnostic sensitivity for all coding GNAS mutations, enhanced by deep sequencing and rigorous bioinformatics under UAE PDPL privacy safeguards.
Our laboratory utilises Illumina NovaSeq platform with 100x mean coverage, validated against international reference standards, ensuring clinically actionable results. The report includes variant classification per ACMG guidelines, reviewed by a DHA-licensed Consultant Medical Genetics.
3. Who should consider this test?
Individuals with phenotypic features of AHO (short stature, round facies, brachydactyly) and normal calcium to confirm pseudopseudohypoparathyroidism, or those with a family history of such conditions.
This test is also valuable for asymptomatic relatives of affected individuals, couples seeking reproductive genetic counselling, and researchers validating clinical phenotypes. A pre‑consultation with an endocrinologist or clinical geneticist is mandatory.
UAE Regulatory & Data Privacy Adherence
This service is fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for genomic data confidentiality, and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All processes are accredited under ISO 9001:2015 and DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | GNAS Gene Pseudopseudohypoparathyroidism NGS Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card |
| Methodology Used | Next Generation Sequencing (NGS) – Illumina NovaSeq, 100x coverage |
| ICD-10-CM Code | E20.8 (Other specified disorders of parathyroid gland) |
| LOINC Code | 21663-4 (GNAS gene mutation analysis) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians